News/ News/ R&D Cantex secures license to develop small molecule-drug for inflammatory lung diseases Eloise McLennan asthma, infection, lung diseases, pharma, small molecule 0 Comment Clinical stage pharmaceutical company Cantex Pharmaceuticals has obtained a global licence from Harvard University’s Office of Technology Development Share X Cantex secures license to develop small molecule-drug for inflammatory lung diseases https://pharmaphorum.com/news/cantex-secures-license-to-develop-small-molecule-drug-for-inflammatory-lung-diseases/